)
Edge20 Mar 2026
Tetra Pak: The Shape of Innovation
The story of Tetra Pak, the Rausing family, and how a paper tetrahedron gave rise to a company that now delivers almost 180 billion packages a year.
Coegin Pharma
Coegin Pharma (COEGIN) investor relations material
Coegin Pharma Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary26 Feb, 2026
Executive summary
Transitioned from research-focused biotech to a commercially driven innovation platform with products on the market and scalable production in place.
Achieved first commercial deliveries and initiated consumer pre-orders for Follicopeptide Gel Serum in Q4 2025.
Strengthened financing and entered 2026 with a clear focus on disciplined execution, scalable growth, and long-term value creation.
Financial highlights
Net revenue for Q4 2025 was 79 TSEK, compared to 0 TSEK in Q4 2024; full year 2025 revenue also 79 TSEK.
Operating profit for Q4 2025 was -6,856 TSEK (Q4 2024: -7,136 TSEK); full year 2025 operating profit was -20,452 TSEK (2024: -23,333 TSEK).
Earnings per share for Q4 2025 was -0.28 SEK (Q4 2024: -0.29 SEK); full year 2025 EPS was -0.82 SEK (2024: -1.26 SEK).
Cash and cash equivalents at year-end 2025 were 7,923 TSEK (2024: 19,679 TSEK).
Equity ratio at year-end 2025 was 35.55% (2024: 93.42%).
Outlook and guidance
2026 will focus on structured expansion, increased production capacity, and additional distribution partnerships.
Portfolio strategy to broaden commercial footprint, with new Follicopeptide products and NPP-4 launch targeted for late 2026.
Directed share issue post-period strengthens liquidity, supporting accelerated production scale-up and working capital.
Aim to achieve balanced cash flow in the second half of 2026, reducing reliance on external financing.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Coegin Pharma
- Follicopeptide targets a Q4 2025 launch in Europe and the U.S., with strong clinical results and partner support.COEGIN
Status Update10 Jan 2026 - Shifted to commercial operations with first Follicopeptide orders and improved financials.COEGINQ3 202520 Nov 2025
- On track for hair growth product launch, costs cut 80%, and cash runway secured into Q2 2026.COEGINQ2 202521 Aug 2025
- Major milestones and financing position Coegin Pharma for product launches in 2025–2026.COEGINQ3 202413 Jun 2025
- FOL005 launch preparations and new partnerships drive progress amid improved financials.COEGINQ2 202413 Jun 2025
- Follicopeptide launch on track, with improved Q1 results and strong market positioning.COEGINQ1 20256 Jun 2025
- 2024 set the stage for Coegin Pharma's commercial leap with Follicopeptide and NPP-4.COEGINQ4 20246 Jun 2025
Next Coegin Pharma earnings date
Q1 202621 May, 2026
Coegin Pharma
Next Coegin Pharma earnings date
Q1 202621 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage